ArticleOncoimmunology

A PI3K p110α-selective inhibitor enhances the efficacy of anti-HER2/neu antibody therapy against breast cancer in mice.

Jae-Hyeog Choi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.